![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
S Yamano, T Aoyama, OW McBride, JP Hardwick, HV Gelboin and FJ Gonzalez
Laboratory of Molecular Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892.
The cDNA containing the full coding sequence of human NADPH-P450 oxidoreductase was isolated and completely sequenced. The cDNA contained 2398 base pairs, including 9 and 358 base pairs of 5' and 3' noncoding sequences, respectively. The human NADPH-P450 oxidoreductase protein deduced from the cDNA has 677 amino acids, with a calculated molecular weight of 76,656. The cDNA nucleotide and deduced amino acid sequences displayed 83 and 92% similarities, respectively, with those of the rat NADPH-P450 oxidoreductase. By use of somatic cell hybrids, the NADPH-P450 oxidoreductase gene was regionally localized to human chromosome 7 (7p15-q35). The levels of NADPH-P450 oxidoreductase protein and mRNA were analyzed in 13 human liver specimens and less than 3-fold variation was found among the different livers. The NADPH- P450 oxidoreductase cDNA was inserted into vaccinia virus and expressed in cell culture. The cDNA-expressed enzyme was active in reducing the electron acceptor cytochrome c. In addition, the NADPH-P450 oxidoreductase stimulated the enzymatic activity of vaccinia virus- expressed human P3(450) when both recombinant viruses were used to coinfect human cells in culture. An approximate equal mole level of NADPH-P450 oxidoreductase and P3(450) was required to achieve maximal activity for both ethoxycoumarin O-deethylase and aryl hydrocarbon hydroxylase.
This article has been cited by other articles:
|
|
 |
|
  H. A. Seow, M. F. Belcourt, P. G. Penketh, W. F. Hodnick, M. Tomasz, S. Rockwell, and A. C. Sartorelli Nuclear Localization of NADPH:Cytochrome c (P450) Reductase Enhances the Cytotoxicity of Mitomycin C to Chinese Hamster Ovary Cells Mol. Pharmacol., February 1, 2005; 67(2): 417 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wu, J. Gu, H. Cui, Q.-Y. Zhang, M. Behr, C. Fang, Y. Weng, K. Kluetzman, P. J. Swiatek, W. Yang, et al. Transgenic Mice with a Hypomorphic NADPH-Cytochrome P450 Reductase Gene: Effects on Development, Reproduction, and Microsomal Cytochrome P450 J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 35 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fukami, R. Horikawa, T. Nagai, T. Tanaka, Y. Naiki, N. Sato, T. Okuyama, H. Nakai, S. Soneda, K. Tachibana, et al. Cytochrome P450 Oxidoreductase Gene Mutations and Antley-Bixler Syndrome with Abnormal Genitalia and/or Impaired Steroidogenesis: Molecular and Clinical Studies in 10 Patients J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 414 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Jounaidi and D. J. Waxman Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy Cancer Res., January 1, 2004; 64(1): 292 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Jounaidi and D. J. Waxman Frequent, Moderate-Dose Cyclophosphamide Administration Improves the Efficacy of Cytochrome P-450/Cytochrome P-450 Reductase-based Cancer Gene Therapy Cancer Res., June 1, 2001; 61(11): 4437 - 4444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Jounaidi and D. J. Waxman Combination of the Bioreductive Drug Tirapazamine with the Chemotherapeutic Prodrug Cyclophosphamide for P450/P450-Reductase-based Cancer Gene Therapy Cancer Res., July 1, 2000; 60(14): 3761 - 3769. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. T. M. Buters, S. Sakai, T. Richter, T. Pineau, D. L. Alexander, U. Savas, J. Doehmer, J. M. Ward, C. R. Jefcoate, and F. J. Gonzalez Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas PNAS, March 2, 1999; 96(5): 1977 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Wang, D. J. Newton, N. Y. Liu, M. Shou, T. Rushmore, and A. Y. H. Lu Inhibitory Anti-CYP3A4 Peptide Antibody: Mapping of Inhibitory Epitope and Specificity Toward Other CYP3A Isoforms Drug Metab. Dispos., February 1, 1999; 27(2): 167 - 172. [Abstract] [Full Text]
|
|
|
|
 |
|
 L McLaughlin, B Burchell, M Pritchard, C. Wolf, and T Friedberg Treatment of mammalian cells with the endoplasmic reticulum-proliferator compactin strongly induces recombinant and endogenous xenobiotic metabolizing enzymes and 3-hydroxy-3-methylglutaryl-CoA reductase in vitro J. Cell Sci., January 2, 1999; 112(4): 515 - 523. [Abstract] [PDF]
|
|
|
|
 |
|
 J. C. Willey, E. L. Coy, M. W. Frampton, A. Torres, M. J. Apostolakos, G. Hoehn, W. H. Schuermann, W. G. Thilly, D. E. Olson, J. R. Hammersley, et al. Quantitative RT-PCR Measurement of Cytochromes p450 1A1, 1B1, and 2B7, Microsomal Epoxide Hydrolase, and NADPH Oxidoreductase Expression in Lung Cells of Smokers and Nonsmokers Am. J. Respir. Cell Mol. Biol., July 1, 1997; 17(1): 114 - 124. [Abstract] [Full Text]
|
|
|
|
|
|
K. A. O'Leary, H.-C. Li, P. A. Ram, P. McQuiddy, D. J. Waxman, and C. B. Kasper Thyroid Regulation of NADPH:Cytochrome P450 Oxidoreductase: Identification of a Thyroid-Responsive Element in the 5'-Flank of the Oxidoreductase Gene Mol. Pharmacol., July 1, 1997; 52(1): 46 - 53. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
